Cheaper macular degeneration treatment may be as effective

Share this article:
The cancer drug Avastin could be as effective as the more expensive Lucentis at improving the vision of seniors with macular degeneration, according to a report from The New York Times.

Lucentis has been approved to treat the eye disease, while physicians have used Avastin as an off-label drug. They say the latter appears to work as well as Lucentis, with the difference coming down to cost: Lucentis costs $2,000 per injection into the eye, while Avastin costs $50.

The National Eye Institute sponsored a randomized trial involving 1,200 patients to compare the two drugs, and the results will be revealed this Sunday at the Association for Research in Vision and Ophthalmology in Fort Lauderdale, FL. While the findings are being kept secret, two people familiar with the results told the New York Times that improved vision resulted from either drug. Patients in the study are being followed for a second year.

The results could mean costs savings for Medicare. In 2008, Medicare paid $20 million for 480,000 Avastin injections for treatment of the eye disease, compared with $537 million for 337,000 Lucentis injections, according to a University of Miami study.

 

Share this article:

More in News

MedPAC discusses limiting patients' post-acute options

MedPAC discusses limiting patients' post-acute options

Medicare rules might have to be relaxed to give hospitals more say in where patients go for post-acute care, members of the Medicare Payment Advisory Commission proposed at a recent ...

Nursing home workers told not to touch residents due to Ebola concerns

U.S. nursing home workers who hail from West Africa are being stigmatized as potential Ebola carriers and forbidden from touching residents, according to IRIN, an independent news service launched by the United Nations Office for the Coordination of Humanitarian Affairs.

Former office manager charged with embezzling half a million dollars from residents

The former business office manager of a Michigan nursing home has been charged with embezzling more than $460,000 from the resident trust fund, the state's attorney general announced last Thursday.